Is The Downturn A ‘Darwinian Moment’ For Biotech? The View From The Frontline
Cutbacks And Threat Of Closure Hitting Small To Medium Biotechs
Executive Summary
After the boom of 2020 and 2021, the biotech sector is experiencing one of the deepest and longest downturns but there are hopes that catalysts could soon revive confidence.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: will biotech overcome its slump?; Sanofi on the future of vaccines; J&J’s M&A ambitions; interview with a Korean immuno-oncology challenger; and a setback for the IL-2 approach in oncology.
As Biotech M&A Activity Gingerly Rises, Regeneron Makes Moves On Checkmate
Regeneron hopes to bolster its immuno-oncology pipeline with the acquisition of Checkmate, which joins a spate of similar deals suggesting renewed interest in biotech investment despite an industry-wide slowdown.
Orchard and Zealand Join Growing List Of Biotechs On The Ropes
Orchard and Zealand are the latest European players to succumb to a financial pinch in the biotech sector, streamlining their pipelines and laying off staff to save on expenses.